Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10662861 | 0.94 | NAAA (0.47) | ALDH1A1ATMTSHRHCAR2NAAA | |
| SCHEMBL7871772 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL31112385 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL21060940 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL7774471 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL1783419 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL7860524 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL5615669 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL27572350 | 0.91 | NAAA (0.48) | ALDH1A1TSHRHCAR2NAAALMNA | |
| SCHEMBL2689929 | 0.88 | HCAR2 (0.36) | ALDH1A1TSHRHCAR2TDP1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250158-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Nicox S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106470-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106470-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
| EP-1534717-B1 | BETA-LACTAMASE INHIBITOR PRODRUG | PFIZER PROD INC (US) | 2006-12-27 | — | — | EP | disclosed |
| US-7091197-B2 | Beta-lactamase inhibitor prodrug | PFIZER INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1636240-A1 | BETA-LACTAMASE INHIBITOR PRODRUG | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1534717-A1 | BETA-LACTAMASE INHIBITOR PRODRUG | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050004093-A1 | Beta-lactamase inhibitor prodrug | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004108733-A1 | BETA-LACTAMASE INHIBITOR PRODRUG | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040110740-A1 | Beta-lactamase inhibitor prodrug | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004018484-A1 | BETA-LACTAMASE INHIBITOR PRODRUG | PFIZER PRODUCTS INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| CN-1007893-B | Process for preparation of ether matrix of anti-inflammatory oxacikam | PFIZER (US) | 1990-05-09 | — | — | CN | disclosed |
| EP-0147177-B1 | ETHER PRODRUGS OF ANTI-INFLAMMATORY OXICAMS | PFIZER INC. (US) | 1987-10-14 | — | — | EP | disclosed |
| CN-85102030-A | The preparation method of the ethers parent medicine of antiphlogiston Xi Kamu | — | 1987-01-31 | — | — | CN | disclosed |
| US-4612143-A | Process for the preparation of fluoroformates | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1986-09-16 | — | — | US | disclosed |
| US-4551452-A | Anti-inflammatory 2-methyl-2H-1,2-benzo-(or -thieno-)thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor | PFIZER INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0147177-A2 | Ether prodrugs of anti-inflammatory oxicams | PFIZER INC. (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004093-A1 | Beta-lactamase inhibitor prodrug | SI, CMBL, STS | ALDH1A1 519/4885ATM 3852/4885TSHR 4591/4885 |
| US-20040110740-A1 | Beta-lactamase inhibitor prodrug | SI, CMBL, STS | ALDH1A1 335/4885ATM 3968/4885TSHR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.